Back to journals
Academic JournalOpen Access

Journal of Comparative Effectiveness Research

2 Papers Indexed in Blossom

Published Papers

Open Accessmeta

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression

Using ESCAPE-TRD trial data in an Excel-based model, esketamine nasal spray plus an oral antidepressant achieved a 50% remission rate at 32 weeks versus 33% for quetiapine XR plus an oral antidepressant. The model estimated lower cost-per-remitter for esketamine (about $3,102 lower in a commercial setting and $456 lower in Medicaid), suggesting esketamine plus an oral antidepressant is cost‑effective for adults with treatment‑resistant depression.

Published
Journal
Journal of Comparative Effectiveness Research
Authors
Clemens, K., Teeple, A., Rive, B., Kirson, N., Desai, U., Doran, J., Eid, D., Qu, A., Bowrey, H., Joshi, K.
Open Accessmeta

Impact analysis of expanded access to ketamine for treatment-resistant depression

Using a population-level Markov model, the study estimates that expanding intravenous ketamine access for US patients with nonpsychotic, treatment‑resistant moderate-to-severe depression would increase treated patients and, over five years, produce net societal savings of approximately $828.2 million annually compared with electroconvulsive therapy (about $95.3M to patients and $743.7M to payers), while adding a modest $10.8M annual caregiver-time burden. Ketamine was projected to be non‑inferior to ECT in improving depressive symptoms.

Published
Journal
Journal of Comparative Effectiveness Research
Authors
Lu, T., D'angelo, S., Tayebali, Z., Dempsey, M., Giombi, K., Khavjou, O.

Quick Facts

Papers Indexed
2
h-Index
39
Open Access
Yes
Publisher
Becaris Publishing
Country
United Kingdom
Website
Visit